By 2040, Saudi Arabia will position itself as the leading global biotechnology hub, marking a beginning of a transformational journey for the biotechnology landscape. With the National Biotechnology S
...
Moving an allogeneic cell therapy from breakthrough research at the bench to a multi-center, global Phase 3 clinical trial is incredibly complex. If you don't have a proven roadmap for international c
...
As the race to develop next-generation cell and gene therapies accelerates, one of the biggest bottlenecks remains patient identification and trial recruitment. Increasingly, sponsors are looking beyo
...
Advancing Rare Disease & Orphan Therapy Innovation in the Middle East
The Middle East is rapidly becoming a hub for rare disease and orphan therapy innovation, driven by high prevalence of inherited disorders, ambitious national genomics programs, and a growing life sci
...
Today, most cell and gene therapies are manufactured in a small number of locations in the US and Europe, creating global supply bottlenecks that delay patient access and increase costs. Across the wo
...
Building a fully integrated cell and gene therapy ecosystem is one of the most complex challenges facing emerging biotech markets today. But translating academic research into scalable, sustainable in
...
In this session, learn how early stage biotechs can design scalable manufacturing platforms from day 1 with the ultimate goal of driving therapy costs under $20000 and discover key lessons and mistake
...
In the Kingdom, investment decisions are increasingly shaped by long-term national priorities aligned with Saudi Vision 2030 and the National Biotechnology Strategy. Investors are not only evaluating
...
The global advanced therapy market is highly fragmented. While Europe possesses world-class scientific research, complex regulatory bottlenecks have historically choked commercialization'causing the E
...
What would convince equipment providers, GMP modular builders, and platform developers to establish local operations? A discussion on incentives, partnerships, and long-term strategic positioning.
Discover how investors can create meaningful returns while supporting Saudi Arabia's biotech ambitions. This session dives into early-stage portfolio strategies, risk management, and how to select ven
...
China has become one of the fastest-growing cell and gene therapy markets in the world, with a rapidly expanding pipeline, significant investment, and a growing number of clinical trials. However, reg
...
' Step by step pathway for regulatory, clinical, manufacturing, commercial entry ' What documentation, partnerships, and timelines global biotechs should expect ' Practical do's/don'ts based on typica
...
For decades, the US has been the undisputed engine of biotech innovation'dominating venture capital flows, clinical development, and the commercialization of breakthrough therapies. But as costs rise
...
What types of global tenants KSA should attract (CDMOs, modality specialists, platforms) What tenants require: incentives, infrastructure, labor, demand guarantee Lessons from Singapore, Ireland, Kore
...
For years, regulation has been viewed as one of the biggest barriers to bringing advanced therapies to patients'slow approval timelines, rigid frameworks, and fragmented global pathways. But across se
...
Saudi Arabia is taking a bold step in advanced therapies with the Kingdom's first national cell and gene therapy hub at King Faisal Specialist Hospital. Once operational, the facility will deliver 2,4
...
The science behind advanced cell therapies has been proven, but commercial sustainability is currently hitting a massive wall: manufacturing. Traditional production is heavily dependent on manual inte
...
Countries such as Saudi Arabia and the United Arab Emirates are rapidly emerging as credible destinations for global clinical research, supported by national strategies like Saudi Vision 2030 and UAE
...
As the cell and gene therapy industry scales from breakthrough science to global manufacturing and commercial delivery, one challenge continues to loom large: talent. From bioprocess engineers and reg
...
AI has the potential to transform cell and gene therapy manufacturing ' from optimising bioprocessing and quality control to reducing costs and scaling production. For the Middle East, this presents a
...
Advanced therapies don't succeed in isolation. They thrive within interconnected ecosystems that span discovery, translational science, manufacturing, regulation, and patient access. This session expl
...
Join the industry in Barcelona | 7 - 9 September 2026 for 3 days of deal-making, data-driven insight and serious momentum across cell and gene therapy. From early science to commercial scale, this is where the full ecosystem connects, collaborates and moves the field forward.
